STAT+: The future of Apellis Pharma’s eye disease treatment is clouded by divergent study results

Apellis Pharmaceuticals has a good news-bad news problem involving its experimental treatment for geographic atrophy — a chronic eye disease and a leading cause of blindness in older people.

Two large and identically designed Phase 3 clinical trials produced confounding results: One study showed Apellis’ drug, injected into the eye, was a success — significantly slowing the progression of the disease compared to a sham injection. But the drug failed to show a benefit in the other study, albeit narrowly.

Continue to STAT+ to read the full story…